Arnica Clinical Trials Recruiting Now

Arnica trials recruiting now

1 registration that name arnica as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.

Trial Finder Read from ClinicalTrials.gov Oct 20, 2026 The Arnica supplement page

Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.

RecruitingNCT06822478

Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis II.

Phase 3
Universidad de Antioquia
About 96 people
Started Mar 11, 2026

In plain words A Phase 3 study of arnica in people 12 and older, run by Universidad de Antioquia. It plans to enroll about 96 people at 1 site, none in the US.

Who it lists and where

Who the trial lists, as registered

Lists people 12 and older. Conditions: Leishmaniasis, Cutaneous.

What it tests, as registered

Arnica Tincture; Meglumine antimoniate.

Registered summary

Cutaneous leishmaniasis (CL) is a parasitic disease caused by more than 20 different species of the protozoan parasite Leishmania. CL usually begins with a papule at the site of the sandfly bite, which enlarges to form a nodule that progresses to an ulceration, or a scaly or warty plaque, over a period of 1 to 3 months. The exact incidence of CL is not known. An estimated 1.2 million cases/year in approximately 100 countries worldwide suffer from different forms of CL. More than 90% of CL cases occur in the Americas and Eastern Mediterranean regions. The full summary is on the listing.

Where, as registered

No US site; Colombia (1).